Article Figures & Data
Figures
- FIGURE 1.
(A) Biodistribution of 111In-DTPA-D2B-IRDye800CW (0.55 MBq, 2.0 μg/mouse) in mice with subcutaneous PSMA-positive LNCaP and PSMA-negative PC3 xenografts at several time points after injection. Excess of unlabeled D2B IgG (300 μg/mouse) was coinjected in one group of mice as negative control. LNCaP-to-PC3 tumor ratios at 48 h after injection were 2.5 ± 0.7. (B) PSMA-positive and PSMA-negative tumor-to-blood ratios at several time points after injection of 111In-DTPA-D2B-IRDye800CW. (C) For illustration purposes, NIRF image of a mouse bearing a PSMA-positive LNCaP tumor on right flank (green arrow) and a PSMA-negative PC3 tumor on the left flank (blue arrow) at 48 h after intravenous injection of dual-labeled 111In-DTPA-D2B-IRDye800CW. *P < 0.0001 on t testing. **P < 0.0001 on t testing. ***P < 0.0001 on t testing. p = photons; p.i. = after injection; sr = steradian; xs = excess.
- FIGURE 2.
Dual-modality fluorescence and micro-SPECT/CT imaging with dual-labeled 111In-DTPA-D2B-IRDye800CW at 48 h after injection in a mouse with an intraperitoneally growing LS174T-PSMA tumor. Shown are NIRF image (acquisition time, 5 min) (A), corresponding micro-SPECT/CT image with mouse supine (B), and NIRF image of muscle sample (top) and tumor (bottom) after resection (C). Green arrows indicate the PSMA-positive tumor. p = photons; sr = steradian.
- FIGURE 3.
Dual-modality fluorescence and micro-SPECT/CT imaging with dual-labeled 111In-DTPA-D2B-IRDye800CW at 48 h after injection in a mouse with several intraperitoneal LS174T-PSMA tumors located at different depths in the peritoneal cavity. NIRF image (acquisition time, 5 min) (A) and corresponding micro-SPECT/CT images in supine (B) and left lateral (C) positions show limited penetration depth of NIRF imaging. Arrows indicate 2 tumors superficial enough to be visualized with fluorescence imaging. Tumors deeper inside peritoneal cavity are not visualized.
- FIGURE 4.
Dual-modality fluorescence and micro-SPECT/CT imaging with dual-labeled 111In-DTPA-D2B-IRDye800CW at 48 h after injection in mouse with intraperitoneally growing LS174T-PSMA tumors. Shown are micro-SPECT/CT image of 3 intraperitoneal PSMA-positive tumors (green and blue arrows) (A), merged photograph and NIRF image of mouse before resection of 3 tumors (B), micro-SPECT/CT image after resection of tumors (C), merged photograph and NIRF image of mouse after resection of tumors (D), merged photograph and optical fluorescence image of tumors after resection (E), and biodistribution of 111In-DTPA-D2B-IRDye800CW in mice with intraperitoneal LS174T-PSMA tumors (F). p = photons; p.i. = after injection; sr = steradian.
Jump to section
Related Articles
Cited By...
- Precision Surgery Guided by Intraoperative Molecular Imaging
- Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
- A Dual-Modality Linker Enables Site-Specific Conjugation of Antibody Fragments for 18F-Immuno-PET and Fluorescence Imaging
- In Vitro and In Vivo Characterization of an 18F-AlF-Labeled PSMA Ligand for Imaging of PSMA-Expressing Xenografts
- Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer
- PSMA-11-Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer
- Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors
- Detection of Micrometastases Using SPECT/Fluorescence Dual-Modality Imaging in a CEA-Expressing Tumor Model
- Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study
- Fluorescent Image-Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time
- Pretargeted Dual-Modality Immuno-SPECT and Near-Infrared Fluorescence Imaging for Image-Guided Surgery of Prostate Cancer